Merck & Co. (MRK) : Halbert Hargroverussell reduced its stake in Merck & Co. by 12.47% during the most recent quarter end. The investment management company now holds a total of 6,318 shares of Merck & Co. which is valued at $340,414 after selling 900 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 12, 2016.Merck & Co. makes up approximately 0.12% of Halbert Hargroverussell’s portfolio.
Other Hedge Funds, Including , Rench Wealth Management reduced its stake in MRK by selling 167 shares or 0.52% in the most recent quarter. The Hedge Fund company now holds 31,911 shares of MRK which is valued at $1.7 Million. Merck & Co. makes up approx 1.44% of Rench Wealth Management’s portfolio.Risk Paradigm Group reduced its stake in MRK by selling 133 shares or 9.61% in the most recent quarter. The Hedge Fund company now holds 1,251 shares of MRK which is valued at $67,404. Merck & Co. makes up approx 0.09% of Risk Paradigm Group’s portfolio.Shufro Rose Co boosted its stake in MRK in the latest quarter, The investment management firm added 15,314 additional shares and now holds a total of 23,938 shares of Merck & Co. which is valued at $1.3 Million. Merck & Co. makes up approx 0.15% of Shufro Rose Co’s portfolio.Airain Ltd reduced its stake in MRK by selling 104,832 shares or 52.87% in the most recent quarter. The Hedge Fund company now holds 93,441 shares of MRK which is valued at $5 Million. Merck & Co. makes up approx 0.35% of Airain Ltd’s portfolio.
Merck & Co. opened for trading at $54.83 and hit $55.54 on the upside on Friday, eventually ending the session at $55.11, with a gain of 0.97% or 0.53 points. The heightened volatility saw the trading volume jump to 86,33,110 shares. Company has a market cap of $152,546 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.